Karyopharm Therapeutics Inc (NASDAQ:KPTI) has received an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.50.

KPTI has been the subject of several research reports. Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, October 18th. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. Finally, initiated coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 price objective for the company.

In other news, insider Sharon Shacham sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total value of $103,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christopher Brett Primiano sold 27,042 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total transaction of $277,991.76. Following the completion of the sale, the senior vice president now directly owns 11,381 shares of the company’s stock, valued at approximately $116,996.68. The disclosure for this sale can be found here. In the last three months, insiders sold 78,542 shares of company stock valued at $819,692. Corporate insiders own 14.71% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC grew its stake in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after buying an additional 4,444 shares during the period. Wells Fargo & Company MN grew its stake in shares of Karyopharm Therapeutics by 18.8% in the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock valued at $298,000 after buying an additional 4,902 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after buying an additional 5,586 shares during the period. California State Teachers Retirement System grew its stake in shares of Karyopharm Therapeutics by 12.2% in the 2nd quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock valued at $542,000 after buying an additional 6,500 shares during the period. Finally, New York State Common Retirement Fund grew its stake in shares of Karyopharm Therapeutics by 33.6% in the 2nd quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock valued at $255,000 after buying an additional 7,099 shares during the period. 57.85% of the stock is owned by institutional investors and hedge funds.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded up $0.97 during midday trading on Wednesday, reaching $14.17. 564,500 shares of the company traded hands, compared to its average volume of 224,589. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $14.85. The stock has a market cap of $653.84, a PE ratio of -5.35 and a beta of 4.11.

WARNING: “Karyopharm Therapeutics Inc (KPTI) Receives Average Rating of “Buy” from Brokerages” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/02/14/karyopharm-therapeutics-inc-kpti-receives-average-rating-of-buy-from-brokerages.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.